Celeste Decker

1.1k citations

21 papers · 685 indexed · h-index 17

Impact in

Physiology top 5%
- Lysosomal Storage Disorders Research
Rheumatology top 5%
- Glycogen Storage Diseases and Myoclonus

Papers in ⓘ

Physiology 19
- Lysosomal Storage Disorders Research 17
Epidemiology 10
- Trypanosoma species research and implications 10

Co-authors: Paul Harmatz (10 shared papers)Nathalie Guffon (5 shared papers)Barbara K. Burton (9 shared papers)Roberto Giugliani (7 shared papers)Christian J. Hendriksz (9 shared papers)Murat Emre (1 shared paper)Simon Jones (5 shared papers)Ida Vanessa Döederlein Schwartz (2 shared papers)
Journals: Molecular Genetics and Metabolism (10 papers)Journal of Inherited Metabolic Disease (2 papers)Orphanet Journal of Rare Diseases (2 papers)Clinical Therapeutics (1 paper)PEDIATRICS (1 paper)
Partner nations: United States United Kingdom Italy

In The Last Decade

Celeste Decker

21 papers receiving 665 citations

Peers

Countries citing papers authored by Celeste Decker

Since Specialization

Citations

This map shows the geographic impact of Celeste Decker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Celeste Decker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Celeste Decker more than expected).

Fields of papers citing papers by Celeste Decker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Celeste Decker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Celeste Decker. The network helps show where Celeste Decker may publish in the future.

Co-authors

The 25 scholars most cited alongside Celeste Decker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Celeste Decker Line = papers co-authored together Celeste Decker links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase Molecular Genetics and Metabolism ·Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz, Nathalie Guffon, Elisa Leão Teles, Clara Sá-Miranda, J. E. Wraith, Michael Beck, Laila Arash, Maurizio Scarpa, David Ketteridge, John J. Hopwood, Barbara Plecko, Robert D. Steiner, Chester B. Whitley, Paige Kaplan, Zi-Fan Yu, Stuart J. Swiedler, Celeste Decker	2008	159
2	The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects Molecular Genetics and Metabolism ·Paul Harmatz, Eugen Mengel, Roberto Giugliani, Vassili Valayannopoulos, Shuan-Pei Lin, Rossella Parini, Nathalie Guffon, Barbara K. Burton, Christian J. Hendriksz, John J. Mitchell, Ana María Martins, Simon Jones, Norberto Guelbert, Ashok Vellodi, Carla E. M. Hollak, Peter Slasor, Celeste Decker	2013	110
3	Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase Journal of Pediatric Rehabilitation Medicine ·Celeste Decker, Zi‐Fan Yu, Roberto Giugliani, Ida Vanessa Döederlein Schwartz, Nathalie Guffon, Elisa Leão Teles, Clara Sá-Miranda, J. E. Wraith, Michael Beck, Laila Arash, Maurizio Scarpa, David Ketteridge, John J. Hopwood, Barbara Plecko, Robert D. Steiner, Chester B. Whitley, Paige Kaplan, Stuart J. Swiedler, Susan E. Conrad, Paul Harmatz	2010	52
4	Effects of Cigarette Smoking on Motor Functions in Patients With Multiple Sclerosis Archives of Neurology ·Murat Emre, Celeste Decker	1992	35
5	Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome Molecular Genetics and Metabolism ·Paul Harmatz, Eugen Mengel, Roberto Giugliani, Vassili Valayannopoulos, Shuan-Pei Lin, Rossella Parini, Nathalie Guffon, Barbara K. Burton, Christian J. Hendriksz, John J. Mitchell, Ana María Martins, Simon Jones, Norberto Guelbert, Ashok Vellodi, Frits A. Wijburg, Kehu Yang, Peter Slasor, Celeste Decker	2014	31
6	Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI Journal of Inherited Metabolic Disease ·Paul Harmatz, Paula Garcia, Nathalie Guffon, Linda M. Randolph, Renée Shediac, Elizabeth Braunlin, Ralph S. Lachman, Celeste Decker	2013	29
7	Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study Clinical Therapeutics ·Brian Long, Troy Tompkins, Celeste Decker, Lynne Jesaitis, Shahid Niaz Khan, Peter Slasor, Paul Harmatz, Charles O’Neill, Becky Schweighardt	2016	26
8	Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria Molecular Genetics and Metabolism ·Roberto T. Zori, Janet A. Thomas, Natasha Shur, William B. Rizzo, Celeste Decker, Orli Rosen, Mingjin Li, Becky Schweighardt, Kevin Larimore, Nicola Longo	2018	25
9	Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study Orphanet Journal of Rare Diseases ·Nicola Longo, Roberto T. Zori, Melissa Wasserstein, Jerry Vockley, Barbara K. Burton, Celeste Decker, Mingjin Li, Kelly Lau, Joy Jiang, Kevin Larimore, Janet A. Thomas	2018	25
10	Impact of long-term elosulfase alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension study Molecular Genetics and Metabolism ·Christian J. Hendriksz, Rossella Parini, Moeenaldeen AlSayed, Julian Raiman, Roberto Giugliani, John J. Mitchell, Barbara K. Burton, Norberto Guelbert, Fiona Stewart, Derralynn Hughes, Robert Matousek, Sara M. Hawley, Celeste Decker, Paul Harmatz	2017	22
11	Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open‐label, phase 2 study American Journal of Medical Genetics Part A ·Paul Harmatz, Eugen Mengel, Tarekegn Geberhiwot, Nicole Muschol, Christian J. Hendriksz, Barbara K. Burton, Elisabeth Jameson, Kenneth I. Berger, Andrea Jester, Marsha Treadwell, Zlatko Sisic, Celeste Decker	2016	22
12	Impact of long‐term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome Journal of Inherited Metabolic Disease ·Christian J. Hendriksz, Kenneth I. Berger, Rossella Parini, Moeenaldeen AlSayed, Julian Raiman, Roberto Giugliani, John J. Mitchell, Barbara K. Burton, Norberto Guelbert, Fiona Stewart, Derralynn Hughes, Robert Matousek, Elaina Jurecki, Celeste Decker, Paul Harmatz	2016	22
13	Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment Molecular Genetics and Metabolism ·Christian J. Hendriksz, Saikat Santra, Simon Jones, Tarekegn Geberhiwot, Lynne Jesaitis, Brian Long, Yulan Qi, Sara M. Hawley, Celeste Decker	2018	21
14	Biomarker analysis of Morquio syndrome: identification of disease state and drug responsive markers Orphanet Journal of Rare Diseases ·Lisa Argento Martell, Kelly Lau, Miranda Mei, Vicki L. Burnett, Celeste Decker, Erik D. Foehr	2011	21
15	Long Term Outcomes of a Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) Molecular Genetics and Metabolism ·Christian J. Hendriksz, Ashok Vellodi, Simon Jones, Hiwot Takkele, S. Lee, Sarah Chesler, Celeste Decker	2012	21
16	Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up Molecular Genetics and Metabolism ·Barbara K. Burton, Nicola Longo, Jerry Vockley, Dorothy K. Grange, Cary O. Harding, Celeste Decker, Mingjin Li, Kelly Lau, Orli Rosen, Kevin Larimore, Janet A. Thomas	2020	19
17	Successful Management of Difficult Infusion-Associated Reactions in a Young Patient With Mucopolysaccharidosis Type VI Receiving Recombinant Human Arylsulfatase B (Galsulfase [Naglazyme]) PEDIATRICS ·Katherine H. Kim, Celeste Decker, Barbara K. Burton	2008	17
18	Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome Journal of Immunological Methods ·Andrew C. Melton, Russell K. Soon, Troy Tompkins, Brian Long, Becky Schweighardt, Yulan Qi, Catherine Vitelli, Anil Bagri, Celeste Decker, Charles O’Neill, Stephen J. Zoog, Lynne Jesaitis	2016	14
19	Relationship Between Patient-Reported Outcomes and Clinical Outcomes in Patients With Morquio A Syndrome SHILAP Revista de lepidopterología ·Christina Lampe, Mohit Jain, Andrew Olaye, Bianca Meesen, Celeste Decker, Eugen Mengel	2015	10
20	BMN 110 (Recombinant Human GALNS), an Investigational Enzyme Replacement Therapy for Mucopolysaccharidosis Type IVA (MPS IVA Or Morquio Syndrome), Promotes Type II Collagen Synthesis in MPS IVA Patients Molecular Genetics and Metabolism ·Florence Lorget, Sung Wook Lee, Kelly Lau, Laurie Tsuruda, Christian J. Hendriksz, Simon Jones, Ashok Vellodi, Sabrina Cheng, Celeste Decker, Charles O’Neill	2012	3

About Celeste Decker

Celeste Decker is a scholar working on Physiology, Epidemiology, Rheumatology, Psychiatry and Mental health and Neurology, having authored 21 papers that have together received 685 indexed citations. Recurring topics across this work include Lysosomal Storage Disorders Research (17 papers), Trypanosoma species research and implications (10 papers), Child Nutrition and Feeding Issues (4 papers), Metabolism and Genetic Disorders (3 papers), Autoimmune and Inflammatory Disorders Research (3 papers), Glycogen Storage Diseases and Myoclonus (3 papers), Cystic Fibrosis Research Advances (2 papers) and Parkinson's Disease Mechanisms and Treatments (2 papers). The work is most often cited by research in Physiology (550 citations), Rheumatology (236 citations), Clinical Biochemistry (69 citations), Epidemiology (258 citations) and Psychiatry and Mental health (98 citations). Celeste Decker has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Paul Harmatz, Nathalie Guffon, Barbara K. Burton, Roberto Giugliani, Christian J. Hendriksz, Murat Emre, Simon Jones, Ida Vanessa Döederlein Schwartz, Chester B. Whitley and Norberto Guelbert. Their work appears in journals such as Molecular Genetics and Metabolism, Journal of Inherited Metabolic Disease, Orphanet Journal of Rare Diseases, Clinical Therapeutics and PEDIATRICS.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact